🚨RECOMMENDED READ🚨 All you need to know about primary ventral and incisional hernias, including detailed open and mini invasive surgical approaches and great illustrations!! ➡️doi.org/10.1093/bjsope… Dont miss this great comprehensive review by Nadia A Henriksen, Heather Bougard,

48yo male. T4 oesophageal SCC with fistula to LMB & LLL. No mets on PET. Has been on chemo for last 3 months, but now deteriorating. Any grand ideas? Is this purely palliative? Pt accepting of any treatment. Lorenzo Ferri MD PhD Tim Underwood Elliot Servais, MD, FACS Ziad Awad, MD, FACS

Oliver M. Fisher, MD, PhD, FMH (Surgery), FRACS aoe.amegroups.org/article/view/5… Here’s our series from a few years ago, now we are up over 25 - will be presented ISDE.net I would probably try from the right. Ventilation is challenging so need jet vent, possibly of both lungs, during the procedure while the airway is open (+/- ECMO)

To all those sharing SANO trial results this week. This summarises why i‘m ignoring the “trial”

ONLY 1 in 1,000 patients with severe #obesity will reach a normal weight through diet and exercise alone. That one person is the one we see promoted and celebrated in the media. We rarely hear the stories of the other 999.

Congrats to all authors on completing what must have been such a challenging trial. So are we done with routine BO surveillance? Barrett’s Oesophagus Surveillance versus endoscopy at need Study (BOSS): a randomized controlled trial - Gastroenterology gastrojournal.org/article/S0016-…

Waited long time for this #RCT comparing pyloroplasty and no pyloroplasty in #MIE #RAMIE 👉pyloroplasty SSAT Fellowship Council SESC & The American Surgeon Emory Surgery Sheraz Markar ISDE.net SAGES is in Tampa in 2026! The Society of Thoracic Surgeons Diseases of the Esophagus Journal The American Foregut Society Pitt Surgery

Very proud to have our hospital contribute some 🇦🇺 patients to this highly relevant trial! Cant wait to see the results!

In extremely honoured to have given the Keynote lecture on Upper GI surgery RACSurgeons meeting in Sydney Australia. Many thanks to Oliver M. Fisher, MD, PhD, FMH (Surgery), FRACS and Clare Bouffler for the invitation.

With routine care, half of patients with compensated MASH cirrhosis & obesity develop major adverse outcomes (MALO—such as liver failure, cancer, transplant, death) in 15 yrs. 🔥Bariatric surgery reduces that risk by 72%. nature.com/articles/s4159… #DDW2025 #EASL2025 #EASLCongress

Enjoying the benign upper gi debates - routine HRM prior to ARS - yes or no? David S Liu. PhD, FRACS doing a great job at arguing the AGAINST position! RACSurgeons #ASC2025

Syed A. Ahmad Experienced/skilled/thoughtful surgeons understand this point. They recognize, pause, plan, and prepare. The more dangerous scenario is the unskilled/inexperienced surgeon - like the turtle on top of the fence post - no idea how they got there, no idea what to do.

x.com/i/article/1923…

Oliver M. Fisher, MD, PhD, FMH (Surgery), FRACS I would also incline to give antibiotics while awaiting appendectomy, even if it means giving it in vein to 124 to prevent one reintervention. Adverse event rate of cef/met is way lower than 1/125. *Even* from economic standpoint it’s 125 ab doses are cheaper than reintervention.

Does the survival actually have anything to do with the surgery? That remains my perennial question with these types of studies…have at least two patients now alive & well in whom I bailed with primaries in situ - 3 years on…tails of survival curves usually biology driven…

Finally back to coding in R for a new & exciting project. Listening to #karmakarmaradio by the one & only SHIMZA. #HappyPlace

🚨 GLP-1s vs Surgery: Who Wins Long Term? - - - A new 2-year comparative study from NYU Langone just dropped—and the results are clear: 📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide): 🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)

Our group was the first to define POSED (Post-Obesity Surgery Esophageal Dysfunction), a newly recognized motility disorder that can develop in a subset of patients after metabolic bariatric surgery. In our latest Neurogastro & Motil Neurogastroenterology & Motility study, we uncover a

Finally, the curved vessel sealer is here. This will be huge, specially in HPB surgery. isrg.intuitive.com/news-releases/… Intuitive

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research